Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Life Sci ; 207: 246-252, 2018 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-29778806

RESUMO

Olanzapine (OLZ), is used in the treatment of bipolar disorder and schizophrenia, diseases that present oxidative stress in their physiopathology. It has low aqueous solubility, which may lead to low oral bioavailability. The search of new drug delivery systems (DDSs) that may increase dissolution rate of OLZ, associated with the investigation of the antioxidant potential of the loaded-systems become of major importance to understand improvement in bipolar disorder and schizophrenia therapy. Thus, this study aimed to evaluate the in vitro antioxidant potential of two different Layered Double Hydroxides (LDH) loaded with 5% of OLZ (CaAl and NiAl), by radical scavenging activity (2,2-Diphenyl-1-picrylhydrazyl and nitric oxid); radical cation scavenging activity (2,2'-azino-bis3-ethylbenzthiazoline-6-sulfonic acid ABTS) and evaluation of inhibition capacity of lipid peroxidation by thiobarbituric acid (TBARS). The results showed that both obtained LDH systems presented in vitro antioxidant capacity when associated with OLZ in all methods performed, and this activity is more pronounced with the systems containing OLZ compared to pure drug. The systems with CaAl was shown to have increased antioxidant potential, compared to NiAl, increasing the antioxidant activity up to 40,83%, 15,84% and 16,73%, as showed by the DPPH, nitric oxide and TBARS tests, respectively. The results revealed that the use of LDHs as a functional excipient may be promising in the pharmaceutical industry for bipolar disorder and schizophrenia therapy.


Assuntos
Alumínio/química , Antioxidantes/química , Benzodiazepinas/química , Cálcio/química , Hidróxidos/química , Níquel/química , Transtorno Bipolar/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Excipientes/química , Sequestradores de Radicais Livres , Humanos , Peroxidação de Lipídeos , Olanzapina , Estresse Oxidativo/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Substâncias Reativas com Ácido Tiobarbitúrico/química
2.
Acta Trop ; 176: 179-187, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28803725

RESUMO

Neglected tropical diseases (NTDs) affect millions of people in different geographic regions, especially the poorest and most vulnerable. Currently NTDs are prevalent in 149 countries, seventeen of these neglected tropical parasitic diseases are classified as endemic. One of the most important of these diseases is schistosomiasis, also known as bilharzia, a disease caused by the genus Schistosoma. It presents several species, such as Schistosoma haematobium, Schistosoma japonicum and Schistosoma mansoni, the latter being responsible for parasitosis in Brazil. Contamination occurs through exposure to contaminated water in the endemic region. This parasitosis is characterized by being initially asymptomatic, but it is able to evolve into more severe clinical forms, potentially causing death. Globally, more than 200 million people are infected with one of three Schistosome species, including an estimated 40 million women of reproductive age. In Brazil, about 12 million children require preventive chemotherapy with anthelmintic. However, according to the World Health Organization (WHO), only about 15% of the at-risk children receive regular treatment. The lack of investment by the pharmaceutical industry for the development and/or improvement of new pharmaceutical forms, mainly aimed at the pediatric public, is a great challenge. Currently, the main forms of treatment used for schistosomiasis are praziquantel (PZQ) and oxaminiquine (OXA). PZQ is the drug of choice because it presents as a high-spectrum anthelmintic, used in the treatment of all known species of schistosomiasis and some species of cestodes and trematodes. OXA, however, is not active against the three Schistosome species. This work presents a literature review regarding schistosomiasis. It addresses points such as available treatments, the role of the pharmaceutical industry against neglected diseases, and perspectives for treatment.


Assuntos
Anti-Helmínticos/uso terapêutico , Doenças Negligenciadas/tratamento farmacológico , Oxamniquine/uso terapêutico , Praziquantel/uso terapêutico , Esquistossomose/tratamento farmacológico , Animais , Pesquisa Biomédica , Brasil , Criança , Feminino , Humanos , Schistosoma haematobium , Schistosoma japonicum , Schistosoma mansoni , Esquistossomose/epidemiologia , Microbiologia da Água
3.
Carbohydr Polym ; 104: 166-74, 2014 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-24607174

RESUMO

Efavirenz (EFV) used as a part of the treatment of first choice in antiretroviral therapy for AIDS has low aqueous solubility and presents problems of absorption. We thus initially present a phase solubility diagram with carriers of different classes. With a view to obtaining a solid dispersion (SD) with suitable consistency to that of a solid formulation, we chose to use PVP K-30, since polymers present some of the best results. The kneading (KN) and solvent evaporation (EV) methods were thus used at different rates. These were characterized by the way of DSC, FT-IR, SEM, DR-X and dissolution. SD EV proved unsatisfactory, resulting in a decreased dissolution rate, despite the amorphous state of the samples, while the SD KN 4:1 (EFV:polymer) and physical mixtures (PM) had a higher rate of dissolution. SD KN and PM 4:1 were also evaluated for stability after storage, with benefits being observed in relation to EFV.


Assuntos
Benzoxazinas/química , Veículos Farmacêuticos/química , Povidona/química , Inibidores da Transcriptase Reversa/química , Alcinos , Ciclopropanos , Solubilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...